T-cell receptor

DGAP-News: Andera Partners' Portfolio Company T-knife Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

Retrieved on: 
Tuesday, August 3, 2021

T-knife plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).

Key Points: 
  • T-knife plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).
  • "We are pleased to be progressing TK-8001 toward the clinic and to advance our broader portfolio of product candidates."
  • "We are highly encouraged by the progress being made at T-knife to advance its important next-generation therapies."
  • T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients.

T-knife Therapeutics Announces $110 Million Series B Financing to Advance Pipeline of T-cell Receptor Therapies

Retrieved on: 
Monday, August 2, 2021

SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing.

Key Points: 
  • SAN FRANCISCO and BERLIN, Aug. 02, 2021 (GLOBE NEWSWIRE) -- T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the successful completion of a $110 million Series B financing.
  • The company plans to use proceeds from the financing to expand its scientific team, increase manufacturing capacity and advance its pipeline of T-cell receptor (TCR) engineered T cell therapies (TCR-T).
  • We are pleased to be progressing TK-8001 toward the clinic and to advance our broader portfolio of product candidates.
  • T-knife is a next-generation T-cell receptor (TCR) company developing a pipeline of therapeutics for solid tumor patients.

TScan Therapeutics to Present Discovery of T Cell Targets for COVID-19 at the Cell-Mediated Therapies for Infectious Disease Summit

Retrieved on: 
Wednesday, July 21, 2021

The Company publishedthese targets in an October 2020 paper in Immunity , showcasing the power of the companys high-throughput T-cell target discovery platform, TargetScan.

Key Points: 
  • The Company publishedthese targets in an October 2020 paper in Immunity , showcasing the power of the companys high-throughput T-cell target discovery platform, TargetScan.
  • The presentation will also feature in vitro data comparing several polyepitope T-cell vaccine candidates based on the Companys novel T cell target discoveries.
  • The Company has also licensed the TCR sequences discovered during this research to Poseida Therapeutics, Inc. to develop allogeneic T-cell therapies for COVID-19.
  • TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer.

BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions

Retrieved on: 
Wednesday, July 7, 2021

BASEL, Switzerland and TBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs).

Key Points: 
  • BASEL, Switzerland and TBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs).
  • For this reason, BioCopy has developed an innovative technology that enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes.
  • With this technology BioCopy is contributing a safety screening for novel TCR-based cancer cell therapies.
  • The goal of this collaboration is to enable the characterization of more than 5,000 different TCR-peptide-HLA interactions simultaneously.

BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions

Retrieved on: 
Wednesday, July 7, 2021

BASEL, Switzerland and TBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs).

Key Points: 
  • BASEL, Switzerland and TBINGEN, Germany, July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NASDAQ: IMTX) "Immatics" in the field of characterization of T cell receptors (TCRs).
  • For this reason, BioCopy has developed an innovative technology that enables high-throughput screening of T cell receptors for binding to a wide variety of peptide-HLA complexes.
  • With this technology BioCopy is contributing a safety screening for novel TCR-based cancer cell therapies.
  • The extension of BioCopy's highly innovative screening platform to provide insight into T cell responses in addition to B-cell responses is a valuable milestone for BioCopy.

Repertoire Immune Medicines Enters Collaboration on Novel Antigen Discovery and T Cell Receptor Research in Multiple Sclerosis

Retrieved on: 
Thursday, April 29, 2021

Researchers from Yale will provide human T cell receptor (TCR) sequences to Repertoire, which will use its proprietary DECODE\xe2\x84\xa2 platform to determine the novel antigens that these TCRs identify.

Key Points: 
  • Researchers from Yale will provide human T cell receptor (TCR) sequences to Repertoire, which will use its proprietary DECODE\xe2\x84\xa2 platform to determine the novel antigens that these TCRs identify.
  • While the cause or causes of MS are not confirmed, it is generally viewed as an autoimmune disease.
  • The company\xe2\x80\x99s repertoire of T cell receptor (TCR)-antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science.
  • In the field of autoimmunity, Repertoire is using its proprietary platform to discover novel epitopes and TCRs from patients with type 1 diabetes.

TScan Therapeutics Strengthens Leadership Team with the Appointment of Brian M. Silver as Chief Financial Officer

Retrieved on: 
Tuesday, February 23, 2021

TScan Therapeutics, Inc. (TScan) a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) in oncology, today announced the appointment of Brian M. Silver as its Chief Financial Officer, effective May 2, 2021.

Key Points: 
  • TScan Therapeutics, Inc. (TScan) a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) in oncology, today announced the appointment of Brian M. Silver as its Chief Financial Officer, effective May 2, 2021.
  • Mr. Silver brings to TScan over 25 years of diverse strategic and financial experience within the healthcare and investment banking sectors.
  • View the full release here: https://www.businesswire.com/news/home/20210223005154/en/
    Im delighted to have Brian join TScan as Chief Financial Officer.
  • I am now excited to deepen my commitment to the Company by joining as Chief Financial Officer.

TScan Therapeutics Appoints Brian M. Silver, J.D., to Its Board of Directors

Retrieved on: 
Thursday, January 7, 2021

TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors.

Key Points: 
  • TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced the appointment of Brian M. Silver, J.D., to its Board of Directors.
  • Mr. Silver is Chief Financial Officer and Head of Corporate Development at Freeline Therapeutics Holdings plc, a clinical-stage systemic gene therapy company.
  • TScan discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases.
  • TScan was co-founded by Board Chair Christoph Westphal (Partner, Longwood Fund) based on pioneering research from the Elledge Lab at Brigham and Womens Hospital.

Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan

Retrieved on: 
Monday, October 12, 2020

The collaboration involves the development of T Cell Receptor (TCR)-T therapy (based on the proprietary TAEST (T cell receptor Affinity Enhancing Specific T cell therapy) technology platform) in Taiwan.

Key Points: 
  • The collaboration involves the development of T Cell Receptor (TCR)-T therapy (based on the proprietary TAEST (T cell receptor Affinity Enhancing Specific T cell therapy) technology platform) in Taiwan.
  • Dr. Johnson Lau, CEO of Athenex, and CEO of Axis Therapeutics, stated, PharmaEssentia represents an important long-term partner of Athenex.
  • We are excited to expand our relationship beyond the Orascovery and Src Kinase platforms to include a collaboration with Axis Therapeutics for the development of TCR-T therapy.
  • The expansion of our relationship to include Axis Therapeutics and its associated TCR-T therapy represents an opportunity to further our successful collaboration.

Ardigen has received funding to accelerate its AI-driven TCR discovery platform for novel cell therapies

Retrieved on: 
Wednesday, September 23, 2020

TCR-based therapies bring hope of effective treatments, especially in solid tumors," said Janusz Homa, CEO of Ardigen.

Key Points: 
  • TCR-based therapies bring hope of effective treatments, especially in solid tumors," said Janusz Homa, CEO of Ardigen.
  • Piotr Stpniak, Immunology Director at Ardigen, adds: "TCR discovery used to consume years and countless laboratory experiments with a lot of dead ends and clinical surprises.
  • The next step for the company is to transform the development of T-cell receptors that target neoantigens for effective and safe adoptive cell therapies.
  • The company's in-house datasets together with advanced AI platforms empower the development of effective precision therapies.